untitled
<OAI-PMH schemaLocation=http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd>
<responseDate>2018-01-15T18:25:30Z</responseDate>
<request identifier=oai:HAL:hal-01259233v1 verb=GetRecord metadataPrefix=oai_dc>http://api.archives-ouvertes.fr/oai/hal/</request>
<GetRecord>
<record>
<header>
<identifier>oai:HAL:hal-01259233v1</identifier>
<datestamp>2017-12-21</datestamp>
<setSpec>type:ART</setSpec>
<setSpec>subject:sdv</setSpec>
<setSpec>collection:UNIV-RENNES1</setSpec>
<setSpec>collection:UNIV-AG</setSpec>
<setSpec>collection:IRSET</setSpec>
<setSpec>collection:HL</setSpec>
<setSpec>collection:IRSET-HIAEC</setSpec>
<setSpec>collection:IFR140</setSpec>
<setSpec>collection:BIOSIT</setSpec>
<setSpec>collection:UR1-UFR-SVE</setSpec>
<setSpec>collection:UR1-HAL</setSpec>
<setSpec>collection:EHESP</setSpec>
<setSpec>collection:USPC</setSpec>
<setSpec>collection:STATS-UR1</setSpec>
<setSpec>collection:UR1-SDV</setSpec>
<setSpec>collection:IRSET-2</setSpec>
<setSpec>collection:UNIV-ANGERS</setSpec>
</header>
<metadata><dc>
<publisher>HAL CCSD</publisher>
<title lang=en>Comparison between liposomal formulations of amphotericin B</title>
<creator>Adler-Moore, Jill P.</creator>
<creator>Gangneux, Jean-Pierre</creator>
<creator>Pappas, Peter G</creator>
<contributor>California Polytechnic State University</contributor>
<contributor>Institut de recherche, santé, environnement et travail [Rennes] (Irset) ; Université d'Angers (UA) - Université des Antilles et de la Guyane (UAG) - Université de Rennes 1 (UR1) - École des Hautes Études en Santé Publique [EHESP] (EHESP) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )</contributor>
<contributor>Service de Parasitologie-Mycologie [Rennes] ; Université de Rennes 1 (UR1) - Hôpital Pontchaillou - CHU Pontchaillou [Rennes]</contributor>
<contributor>The University of Alabama at Birmingham [ Birmingham] (UAB)</contributor>
<description>International audience</description>
<source>Medical Mycology</source>
<identifier>hal-01259233</identifier>
<identifier>https://hal-univ-rennes1.archives-ouvertes.fr/hal-01259233</identifier>
<source>https://hal-univ-rennes1.archives-ouvertes.fr/hal-01259233</source>
<source>Medical Mycology, 2016, 54 (2), pp.223-231. 〈10.1093/mmy/myv111〉</source>
<identifier>DOI : 10.1093/mmy/myv111</identifier>
<relation>info:eu-repo/semantics/altIdentifier/doi/10.1093/mmy/myv111</relation>
<identifier>PUBMED : 26768369</identifier>
<relation>info:eu-repo/semantics/altIdentifier/pmid/26768369</relation>
<language>en</language>
<subject lang=en> bioequivalence</subject>
<subject lang=en>amphotericin B</subject>
<subject lang=en> invasive fungal infections</subject>
<subject lang=en> Liposomes</subject>
<subject lang=en> Leishmaniasis</subject>
<subject>[SDV] Life Sciences [q-bio]</subject>
<type>info:eu-repo/semantics/article</type>
<type>Journal articles</type>
<description lang=en>Given the clinical success of commercial amphotericin B lipid products, investigators have begun making generic formulations of liposomal amphotericin B. Generic medicines are an attractive approach to help decrease the cost and accessibility to healthcare, provided that appropriate studies are performed to ensure bioequivalence with the parent product. This is of particular concern for liposomal drugs such as amphotericin B where liposomes are used as a carrier system to reduce the toxicity of the active agent. A favorable therapeutic profile for this form of the drug has to include the proper chemical composition along with strictly controlled manufacturing processes. Studies have shown that a comparison of liposomal amphotericin B products with different or the same chemical compositions, using different methods of production, will vary in size, and have significantly dissimilar in vitro and in vivo toxicities along with reduced efficacy. These results underscore the importance of establishing appropriate bioequivalence testing for liposome products to ensure uniformity of their therapeutic index</description>
<date>2016</date>
</dc>
</metadata>
</record>
</GetRecord>
</OAI-PMH>
